enGene Appoints New CMO, CSO; Director Departs

TL;DR

enGene beefs up R&D leadership with new CMO/CSO, but a director is out.

AI Summary

On October 16, 2024, enGene Holdings Inc. announced the appointment of Dr. Robert L. Mass as Chief Medical Officer and Dr. David L. Brown as Chief Scientific Officer. The company also reported on the departure of Dr. Robert L. Mass from his role as a director, effective October 16, 2024. These changes are part of the company's ongoing strategic initiatives.

Why It Matters

The appointment of experienced executives in key scientific and medical roles suggests a focus on advancing the company's research and development pipeline. The departure of a director may indicate a shift in board strategy or governance.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can signal shifts in company strategy or internal dynamics, which may introduce uncertainty.

Key Players & Entities

• enGene Holdings Inc. (company) — Registrant
• Dr. Robert L. Mass (person) — Appointed Chief Medical Officer and departed as Director
• Dr. David L. Brown (person) — Appointed Chief Scientific Officer

FAQ

Key Financial Figures

• $11.50 — e Common Share, at an exercise price of $11.50 per Share ENGNW The Nasdaq Stock Ma
• $485,000 — of twelve months, in a total amount of $485,000, to be paid over the length of such ter

Filing Documents

• engn-20241016.htm (8-K) — 52KB
• engn-ex10_1.htm (EX-10.1) — 141KB
• engn-ex99_1.htm (EX-99.1) — 16KB
• img7790613_0.jpg (GRAPHIC) — 203KB
• 0000950170-24-115767.txt ( ) — 637KB
• engn-20241016.xsd (EX-101.SCH) — 46KB
• engn-20241016_htm.xml (XML) — 7KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 21, 2024, the Company issued a press release announcing, among other things, the appointment of Joan Connolly as Chief Technology Officer and certain other executive leadership changes, a copy of which is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. In connection with Dr. Cheung's transition to the role of Chief Scientific Officer, the Company announced the appointment of Joan Connolly as Chief Technology Officer, effective as of October 21, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1* Amended and Restated Employment Agreement, dated October 16, 2024, by and between enGene USA, Inc. and Alexander Nichols. 99.1 Press Release of the Company dated October 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Indicates a management contract or compensatory plan or arrangement.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: October 21, 2024 By: /s/ Lee Giguere Name: Lee Giguere Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR